Professor Mark Emberton
London Urology Associates, 114a Harley Street, London W1G 7JL
Prostate disease (benign and malignant), the non invasive evaluation of men at risk of having prostate cancer, methodological aspects of clinical research, particularly the use of alternatives to the randomised control trial in surgery.
English, Spanish (fluent)
Professor Mark Emberton holds the post of professor in interventional oncology at University College London and is associate professor at Middlesex University, London. At UCLH he is pathway director for urological cancer for UCL Partners. He is also honorary clinical director of the Clinical Effectiveness Unit at the Royal College of Surgeons of England. Prof Emberton’s clinical and research interests are focused mainly on diseases of the prostate gland, both benign and malignant. In prostate cancer much of his activity is at present focused on evaluating minimally invasive therapies for localised prostate cancer.